Targeting Elastin-Derived Peptides Reverses Alveolar Epithelial Dysfunction in Chronic Obstructive Pulmonary Disease

Abstract

Chronic obstructive pulmonary disease (COPD) is characterized by progressive alveolar destruction and defective regeneration, yet the matrix-derived factors contributing to this process remain poorly defined. We investigated the role of elastin-derived peptides (EDPs), bioactive fragments generated during cigarette smoke (CS)-induced elastin degradation, in alveolar epithelial dysfunction. In lung tissues from patients with COPD and in CS-exposed mice, elevated levels of EDPs were associated with elastic fiber disruption and impaired alveolar type 2 (AT2)-to-alveolar type 1 (AT1) differentiation. These observations were supported by histological analyses, single-cell transcriptomic profiling, and organoid-based functional assays. In mouse and human alveolar organoids, CS extract and EDPs each suppressed organoid growth and impaired AT2-to-AT1 differentiation. Mechanistically, EDPs exposure was associated with activation of TLR4/NF-κB signaling, and reduced β-catenin activity, whereas pharmacological inhibition of TLR4 partially restored alveolar epithelial differentiation. Notably, the EDPs-neutralizing agent TB partially rescued AT2-to-AT1 differentiation in organoids and alleviated emphysematous injury in vivo. Together, these findings identify EDPs as an important matrix-derived mediator of alveolar regenerative failure in COPD and support further evaluation of EDP-targeted intervention as a potential strategy for promoting alveolar repair.

Keywords

alveolar repair / alveolar type 2 cells / chronic obstructive pulmonary disease / elastin-derived peptides / peptide-based therapy

References

[1] A. Agustí, B. R. Celli, G. J. Criner, et al., “Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary,” European Respiratory Journal 61, no. 4 (2023): 2300239.

[2] D. Singh, A. Agusti, A. Anzueto, et al., “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: The GOLD Science Committee Report 2019,” European Respiratory Journal 53, no. 5 (2019): 1900164.

[3] J. C. Hogg and W. Timens, “The Pathology of Chronic Obstructive Pulmonary Disease,” Annual Review of Pathology 4 (2009): 435–459.

[4] H. Takiguchi and K. Akata, “Effects of Inhaled Corticosteroid/Long-Acting β2-Agonist Combination on the Airway Microbiome of Patients With Chronic Obstructive Pulmonary Disease: A Randomized Controlled Clinical Trial (DISARM),” American Journal of Respiratory and Critical Care Medicine 204, no. 10 (2021): 1143–1152.

[5] C. Wang, J. Zhou, J. Wang, et al., “Progress in the Mechanism and Targeted Drug Therapy for COPD,” Signal Transduction and Targeted Therapy 5, no. 1 (2020): 248.

[6] C. K. Billington, R. B. Penn, and I. P. Hall, “β_2-Agonists,” in Pharmacology and Therapeutics of Asthma and COPD. Handbook of Experimental Pharmacology vol. 237 (Springer, 2017), 23–40.

[7] M. G. Burt, G. W. Roberts, N. R. Aguilar-Loza, P. Frith, and S. N. Stranks, “Continuous Monitoring of Circadian Glycemic Patterns in Patients Receiving Prednisolone for COPD,” Journal of Clinical Endocrinology and Metabolism 96, no. 6 (2011): 1789–1796.

[8] Y. B. Joshi, M. L. Thomas, D. L. Braff, et al., “Anticholinergic Medication Burden-Associated Cognitive Impairment in Schizophrenia,” American Journal of Psychiatry 178, no. 9 (2021): 838–847.

[9] W. Broekman, P. Khedoe, K. Schepers, H. Roelofs, J. Stolk, and P. S. Hiemstra, “Mesenchymal Stromal Cells: A Novel Therapy for the Treatment of Chronic Obstructive Pulmonary Disease?,” Thorax 73, no. 6 (2018): 565–574.

[10] M. K. Glassberg, I. Csete, E. Simonet, and S. J. Elliot, “Stem Cell Therapy for COPD: Hope and Exploitation,” Chest 160, no. 4 (2021): 1271–1281.

[11] H. P. Van Eeckhoutte, C. Donovan, R. Y. Kim, et al., “RIPK1 Kinase-Dependent Inflammation and Cell Death Contribute to the Pathogenesis of COPD,” European Respiratory Journal 61, no. 4 (2023): 2201506.

[12] C. E. Barkauskas, M. J. Cronce, C. R. Rackley, et al., “Type 2 Alveolar Cells Are Stem Cells in Adult Lung,” Journal of Clinical Investigation 123, no. 7 (2013): 3025–3036.

[13] J. Choi, J. E. Park, G. Tsagkogeorga, et al., “Inflammatory Signals Induce AT2 Cell-Derived Damage-Associated Transient Progenitors That Mediate Alveolar Regeneration,” Cell Stem Cell 27, no. 3 (2020): 366–382.e7.

[14] H. Fehrenbach, “Alveolar Epithelial Type II Cell: Defender of the Alveolus Revisited,” Respiratory Research 2, no. 1 (2001): 33–46.

[15] S. Shao, N. Zhang, G. P. Specht, et al., “Pharmacological Expansion of Type 2 Alveolar Epithelial Cells Promotes Regenerative Lower Airway Repair,” PNAS 121, no. 16 (2024): e2400077121.

[16] H. J. Boo, H. Y. Min, C. S. Park, et al., “Dual Impact of IGF2 on Alveolar Stem Cell Function During Tobacco-Induced Injury Repair and Development of Pulmonary Emphysema and Cancer,” Cancer Research 83, no. 11 (2023): 1782–1799.

[17] H. Yu, Y. Lin, Y. Zhong, et al., “Impaired AT2 to AT1 Cell Transition in PM2.5-Induced Mouse Model of Chronic Obstructive Pulmonary Disease,” Respiratory Research 23, no. 1 (2022): 70.

[18] K. Uemasu, N. Tanabe, K. Tanimura, et al., “Serine Protease Imbalance in the Small Airways and Development of Centrilobular Emphysema in Chronic Obstructive Pulmonary Disease,” American Journal of Respiratory Cell and Molecular Biology 63, no. 1 (2020): 67–78.

[19] R. T. Abboud and S. Vimalanathan, “Pathogenesis of COPD. Part I. The Role of Protease-Antiprotease Imbalance in Emphysema,” International Journal of Tuberculosis and Lung Disease 12, no. 4 (2008): 361–367.

[20] R. P. Mecham, “Elastin in Lung Development and Disease Pathogenesis,” Matrix Biology 73 (2018): 6–20.

[21] H. J. Vindin, B. G. Oliver, and A. S. Weiss, “Elastin in Healthy and Diseased Lung,” Current Opinion in Biotechnology 74 (2022): 15–20.

[22] S. D. Shapiro, N. M. Goldstein, A. M. Houghton, D. K. Kobayashi, D. Kelley, and A. Belaaouaj, “Neutrophil Elastase Contributes to Cigarette Smoke-Induced Emphysema in Mice,” American Journal of Pathology 163, no. 6 (2003): 2329–2335.

[23] X. Guo, S. Yang, H. Zhu, et al., “Involvement of M2 Macrophages Polarization in PM2.5-Induced COPD by Upregulating MMP12 via IL4/STAT6 Pathway,” Ecotoxicology and Environmental Safety 283 (2024): 116793.

[24] A. Le Page, A. Khalil, and P. Vermette, “The Role of Elastin-Derived Peptides in Human Physiology and Diseases,” Matrix Biology 84 (2019): 81–96.

[25] L. E. de Castro Brás and N. G. Frangogiannis, “Extracellular Matrix-Derived Peptides in Tissue Remodeling and Fibrosis,” Matrix Biology 91-92 (2020): 176–187.

[26] L. Nannan, W. Gsell, S. Belderbos, et al., “A Multimodal Imaging Study to Highlight Elastin-Derived Peptide Pro-Tumoral Effect in a Pancreatic Xenograft Model,” British Journal of Cancer 128, no. 11 (2023): 2000–2012.

[27] K. A. Szychowski and J. Gmiński, “Elastin-Derived Peptide VGVAPG Affects the Proliferation of Mouse Cortical Astrocytes With the Involvement of Aryl Hydrocarbon Receptor (Ahr), Peroxisome Proliferator-Activated Receptor Gamma (Pparγ), and Elastin-Binding Protein (EBP),” Cytokine 126 (2020): 154930.

[28] T. Hocine, S. Blaise, C. Hachet, et al., “Lactosylceramide Induced by Elastin-Derived Peptides Decreases Adipocyte Differentiation,” Journal of Physiology and Biochemistry 76, no. 3 (2020): 457–467.

[29] Y. Wang, F. Xue, W. Cheng, et al., “Design and Synthesis of Novel Ultralong-Acting Peptides as EDP-EBP Interaction Inhibitors for Pulmonary Fibrosis Treatment,” Journal of Medicinal Chemistry 67, no. 8 (2024): 6624–6637.

[30] M. A. Dale, W. Xiong, J. S. Carson, et al., “Elastin-Derived Peptides Promote Abdominal Aortic Aneurysm Formation by Modulating M1/M2 Macrophage Polarization,” Journal of Immunology 196, no. 11 (2016): 4536–4543.

[31] R. M. Kelsh and P. J. McKeown-Longo, “Topographical Changes in Extracellular Matrix: Activation of TLR4 Signaling and Solid Tumor Progression,” Trends in Cancer Research 9 (2013): 1–13.

[32] J. Pei, L. Fan, and K. Nan, “Excessive Activation of TLR4/NF-κB Interactively Suppresses the Canonical Wnt/β-Catenin Pathway and Induces SANFH in SD Rats,” Scientific Reports 7, no. 1 (2017): 11928.

[33] C. Le Henaff, R. Mansouri, and D. Modrowski, “Increased NF-κB Activity and Decreased Wnt/β-Catenin Signaling Mediate Reduced Osteoblast Differentiation and Function in ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mice,” Journal of Biological Chemistry 290, no. 29 (2015): 18009–18017.

[34] S. Uniyal, A. Dhasmana, A. Tyagi, and J. P. Muyal, “ATRA Reduces Inflammation and Improves Alveolar Epithelium Regeneration in Emphysematous Rat Lung,” Biomedicine & Pharmacotherapy 108 (2018): 1435–1450.

[35] D. S. Faffe and W. A. Zin, “Lung Parenchymal Mechanics in Health and Disease,” Physiological Reviews 89, no. 3 (2009): 759–775.

[36] M. M. Koenders, R. G. Wismans, B. Starcher, B. C. Hamel, R. P. Dekhuijzen, and T. H. van Kuppevelt, “Fibrillin-1 Staining Anomalies Are Associated With Increased Staining for TGF-β and Elastic Fibre Degradation; New Clues to the Pathogenesis of Emphysema,” Journal of Pathology 218, no. 4 (2009): 446–457.

[37] G. Liu, A. M. Philp, T. Corte, et al., “Therapeutic Targets in Lung Tissue Remodelling and Fibrosis,” Pharmacology & Therapeutics 225 (2021): 107839.

[38] C. M. Bidan, A. C. Veldsink, H. Meurs, and R. Gosens, “Airway and Extracellular Matrix Mechanics in COPD,” Frontiers in Physiology 6 (2015): 346.

[39] P. Lange, E. Ahmed, Z. M. Lahmar, F. J. Martinez, and A. Bourdin, “Natural History and Mechanisms of COPD,” Respirology 26, no. 4 (2021): 298–321.

[40] Q. Feng, Y. Z. Yu, and Q. H. Meng, “Blocking Tumor Necrosis Factor-α Delays Progression of Chronic Obstructive Pulmonary Disease in Rats Through Inhibiting MAPK Signaling Pathway and Activating SOCS3/TRAF1,” Experimental and Therapeutic Medicine 22, no. 5 (2021): 1311.

[41] T. M. Conlon, G. John-Schuster, and D. Heide, “Inhibition of LTβR Signalling Activates WNT-Induced Regeneration in Lung,” Nature 588, no. 7836 (2020): 151–156.

[42] J. T. Benjamin, E. J. Plosa, J. M. Sucre, et al., “Neutrophilic Inflammation During Lung Development Disrupts Elastin Assembly and Predisposes Adult Mice to COPD,” Journal of Clinical Investigation 131, no. 1 (2021): e139481.

[43] J. Chen, T. Wang, X. Li, et al., “DNA of Neutrophil Extracellular Traps Promote NF-κB-Dependent Autoimmunity via cGAS/TLR9 in Chronic Obstructive Pulmonary Disease,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 163.

[44] D. Wojciechowski and A. Wiseman, “Long-Term Immunosuppression Management: Opportunities and Uncertainties,” Clinical Journal of the American Society of Nephrology 16, no. 8 (2021): 1264–1271.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.